Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Pixelgen Technologies AB manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This case is handled by KIRWIN, STEFANIE JOHANNA, who is the busiest examiner for the portfolio with 1 pending action. The company's current prosecution involves 1 distinct examiner and 1 distinct art unit. This narrow focus indicates a specialized technical application within the biotechnology sector.
The pending office action suggests that the company's current intellectual property activity is highly concentrated. Having a single distinct examiner for the entire portfolio means that the outcome of the company's current prosecution depends entirely on the perspective of KIRWIN, STEFANIE JOHANNA. The distinct art unit involved further underscores the specific nature of the technology being claimed. Practitioners should focus on the specific examination history of this art unit to anticipate potential challenges. This streamlined prosecution profile reflects a singular point of contact at the patent office for the company's current filings. The involvement of only one examiner and one art unit simplifies the management of the company's active claims.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIRWIN, STEFANIE JOHANNA | 1 | 15.6% | +29.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19102345 | METHOD FOR FIXING PRIMARY ANTIBODIES TO A BIOLOGICAL SAMPLE | KIRWIN, STEFANIE JOHANNA | 40d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19102345 | METHOD FOR FIXING PRIMARY ANTIBODIES TO A BIOLOGICAL SAMPLE | KIRWIN, STEFANIE JOHANNA | 40d |
| Art Unit | Apps |
|---|---|
| 1677 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19102345 | METHOD FOR FIXING PRIMARY ANTIBODIES TO A BIOLOGICAL SAMPLE | KIRWIN, STEFANIE JOHANNA | 1677 | §103§112 | Non-Final OA | 40d | Pending | Feb 07, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPixelgen Technologies AB has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Stefanie Johanna Kirwin has the most, with 1 of Pixelgen Technologies AB's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
